COMPOSITION FOR ADMINISTRATION OF DOUBLE-STRANDED OLIGONUCLEOTIDE STRUCTURES USING ULTRASONIC NEBULIZER FOR PREVENTION OR TREATMENT OF RESPIRATORY VIRAL INFECTION INCLUDING COVID-19, PULMONARY FIBROSIS CAUSED BY VIRAL INFECTION, OR RESPIRATORY DISEASE
SIRNAGEN THERAPEUTICS CORPORATION (Republic of Korea)
Inventor
Park, Han-Oh
Lee, Sang-Kyu
Yun, Sung-Il
Kwon, Oh Seung
Goh, Eun-Ah
Goh, Young-Ho
Park, Jun-Hong
Song, Kang
Kim, Jangseon
Lee, Mi-Sun
Choi, Soon-Ja
Abstract
The present invention relates to a composition for administering a double-stranded oligonucleotide structure using an ultrasonic nebulizer. According to the method, the double-stranded oligonucleotide according to the present invention forms self-assembled nanoparticles, which are 90 nm in size and have a neutral charge, and it is possible to deliver the double-stranded oligonucleotide specifically to the nasal cavity and lungs while maintaining not only the same concentration, molecular weight, purity, nanoparticle size, and osmolality as those of the stock material but also the target gene inhibitory activity without cytotoxicity. Thus, the present invention may be useful for the prevention or treatment of respiratory viral infections including COVID-19, pulmonary fibrosis caused by viral infection, or respiratory diseases.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
2.
COMPOSITION FOR ALLEVIATING HAIR GRAYING, PROMOTING HAIR GROWTH AND/OR PREVENTING OR ALLEVIATING HAIR LOSS, COMPRISING DOUBLE-STRANDED MIRNA AS ACTIVE INGREDIENT
SIRNAGEN THERAPEUTICS CORPORATION (Republic of Korea)
Inventor
Park, Han-Oh
Lee, Sang-Kyu
Kwon, Oh Seung
Goh, Eun-Ah
Abstract
The present invention relates to a composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded miRNA as an active ingredient and, more specifically, to: miR-3139, miR-3189, miR-3199 or miR-8485, which are double-stranded miRNA; a double-stranded oligonucleotide structure comprising same; or a pharmaceutical or cosmetic composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising nanoparticles containing the structure as an active ingredient. A composition according to the present invention can prevent hair graying and reduce the rate of progress thereof by activating melanocytes and promoting melanogenesis and can allow the hair already affected by graying to be improved to a state before graying. In addition, the composition promotes the activation of melanocytes and the proliferation of dermal papilla cells and keratinocytes that are present in hair follicles, and induces outer root sheath development and hair growth so that the effects of promoting hair growth and/or preventing hair loss can be exhibited.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
3.
ADAPTER FOR MOUNTING CONDUCTIVE PIPETTE, SAMPLE TUBE OPENING/CLOSING DEVICE, AND AUTOMATIC SAMPLE ANALYSIS SYSTEM
The present invention relates to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system and, more specifically, to an adapter for mounting a conductive pipette, a sample tube opening/closing device, and an automatic sample analysis system, in which dispensing of a liquid sample and extraction, amplification and testing of nucleic acids are integrally carried out.In the present invention, disclosed is a sample tube opening/closing device comprising: a housing (110) that forms an inner space isolated from the outside and includes a door (120) for carrying in/out a multi-well plate (20) for biological samples, including a plurality of sample tubes (10) in which biological samples are accommodated; and a sample tube opening/closing part that is installed in the inner space to be spaced apart from the multi-well plate (20) for biological samples and automatically opens and closes the sample tubes (10).
The present invention relates to a nucleic acid amplification test apparatus, and an automatic sample analysis system having same and, more particularly, to a nucleic acid amplification test apparatus in which separation and purification, dispensation, amplification, and testing of samples are performed integrally, and an automatic sample analysis system having same. Disclosed in the present invention is a nucleic acid amplification test apparatus comprising: a housing (30) having an inner space (S1) isolated from the outside; a multi-well plate insertion unit (100) into which a multi-well plate (40) having a plurality of reaction tubes (1) accommodating a target nucleic acid solution is inserted through an automatic purification and dispensing apparatus (10); a sealing plate insertion unit (200) into which a sealing plate (50) having a sealing means for sealing the inlets of the plurality of reaction tubes (1); a fluorescence detection unit (400) disposed on an upper side of the sealing plate insertion unit (200) and detecting a target nucleic acid in the reaction tubes (1); and a temperature control block (500) disposed on a lower side of the multi-well plate insertion unit (100) and controlling the temperature of the reaction tubes (1), wherein the reaction tubes (1) are moved relatively so as to be adjacent to the sealing means to be then sealed by the sealing means.
SIRNAGEN THERAPEUTICS CORPORATION (Republic of Korea)
Inventor
Park, Han-Oh
Kim, Jangseon
Lee, Mi Sun
Choi, Soonja
Lee, Eun-Kwang
Byun, Sang Jin
Abstract
The present invention relates to: a double-stranded oligonucleotide which can highly specifically and efficiently inhibit the proliferation of Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), preferably a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or a DNA/RNA hybrid; a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide; and a use thereof for treating COVID-19.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
SIRNAGEN THERAPEUTICS CORPORATION (Republic of Korea)
Inventor
Park, Jun Hong
Park, Han-Oh
Yun, Sung Il
Kim, Tae Rim
Hwang, Soo Hyun
Song, Kang
Jung, Sang Hyuk
Kim, Jangseon
Lee, Mi Sun
Choi, Soonja
Son, Seung-Seob
Abstract
The present invention relates to a double-stranded oligonucleotide capable of inhibiting amphiregulin expression in a very specific and highly efficient manner, preferably a double-stranded oligonucleotide comprising a sequence in the form of an RNA/RNA, DNA/DNA or DNA/RNA hybrid, and the use of a double-stranded oligonucleotide structure, which comprises the double-stranded oligonucleotide, and nanoparticles, for preventing or treating obesity.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 9/19 - Particulate form, e.g. powders lyophilised
CTGF GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE, AND A COMPOSITION FOR PREVENTING AND TREATING FIBROTIC DISEASES AND RESPIRATORY-RELATED DISEASES COMPRISING SAME
The present invention relates to a double-stranded oligonucleotide capable of inhibiting CTGF expression with a very specific and high efficiency, a double-stranded oligonucleotide structure and nanoparticles comprising the double-stranded oligonucleotide, and a use thereof in preventing or treating of fibrotic or respiratory diseases.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
8.
DOUBLE STRANDED OLIGONUCLEOTIDE CONSTRUCT COMPRISING ANDROGEN RECEPTOR SPECIFIC SEQUENCE, AND COMPOSITION FOR PREVENTING HAIR LOSS AND PROMOTING HAIR GROWTH COMPRISING SAME
A double stranded oligonucleotide construct having a structure of Structural Formula (1): A-X-R-Y-B Structural Formula (1), is provided for preventing hair loss or promoting hair growth. In Structural Formula (1), wherein A is a hydrophilic material, B is a hydrophobic material, each of X and Y independently represents a covalent bond or a linker-mediated covalent bond, and R represents an androgenreceptor-specific oligonucleotide comprising a sense strand comprising SEQ ID NO: 68 or 109 and an antisense strand comprising a sequence complementary thereto.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
9.
AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME
The present invention relates to a double-stranded oligonucleotide which can highly specifically and efficiently inhibit an amphiregulin expression and, preferably, a double-stranded oligonucleotide comprising a sequence in the form of RNA/RNA, DNA/DNA or DNA/RNA hybrid, a double-stranded oligonucleotide structure comprising the double-stranded oligonucleotide, nanoparticles comprising the double-stranded oligonucleotide structure, and a fibrosis or respiratory disease preventive or therapeutic use thereof.
The present invention relates to a pharmaceutical composition for treating cancer comprising, as an active ingredient, at least one miRNA selected from a group consisting of miR-3670, miR-4477a and miR-8078. The pharmaceutical composition for treating cancer according to the present invention has superior effects of suppressing proliferation of cancer cells and inducing destruction of cancer cells. Accordingly, the pharmaceutical composition of the present invention may be effectively used as an anticancer agent.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present invention relates to a pharmaceutical composition for treating cancer comprising, as an active ingredient, at least one miRNA selected from a group consisting of miR-3670, miR-4477a and miR-8078. The pharmaceutical composition for treating cancer according to the present invention has superior effects of suppressing proliferation of cancer cells and inducing destruction of cancer cells. Accordingly, the pharmaceutical composition of the present invention may be effectively used as an anticancer agent.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
RESPIRATORY DISEASE-RELATED GENE SPECIFIC SIRNA, DOUBLE-HELICAL OLIGO RNA STRUCTURE CONTAINING SIRNA, COMPOSITION CONTAINING SAME FOR PREVENTING OR TREATING RESPIRATORY DISEASE
The present invention relates to respiratory diseases, especially to gene specific siRNA related to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), and a highly efficient double-helical oligo RNA structure containing the same, wherein the double-helical oligo RNA structure has a structure in which hydrophilic and hydrophobic materials are bonded at the both ends of the double-helical RNA (siRNA) using a simple covalent bond or a linker-mediated covalent bond to be effectively transferred into a cell, and is converted into nanoparticles by the hydrophobic interaction of the double-helical oligo RNA structure in a solution. It is desirable that the siRNA contained in the double-helical oligo RNA structure is a siRNA specific to a CTGF, Cyr61, or Plekho1, which are genes related to respiratory diseases, particularly idiopathic pulmonary fibrosis and COPD. In addition, the present invention relates to a method for producing the double-helical oligo RNA structure and a pharmaceutical composition containing the double-helical oligo RNA structure for preventing or treating respiratory diseases, particularly idiopathic pulmonary fibrosis and COPD.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 11/00 - Drugs for disorders of the respiratory system
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
13.
IMPROVED NANOPARTICLE TYPE OLIGONUCLEOTIDE STRUCTURE HAVING HIGH EFFICIENCY AND METHOD FOR PREPARING SAME
The present invention relates to an oligonucleotide structure and a method for preparing the same and, more particularly, to an oligonucleotide structure in which a polymer compound is linked to an oligonucleotide via a covalent bond to improve in vivo stability of the oligonucleotide and cellular delivery efficiency of the oligonucleotide; and to a method for preparing the same. The oligonucleotide structure is improved into a homogenous material, thereby solving the problem in material verification due to polydispersion characteristics occurring when a hydrophilic material linked to the oligonucleotide is a synthetic polymer; the nucleotide structure is easy to synthesize compared with the existing process; and the size of a double helix oilgo-RNA structure can be accurately adjusted through the control of the number of repetitions of a hydrophilic material block, and thus, the gene expression regulation function of the oligonucleotide does not deteriorate through the synthesis of the optimized oligonucleotide structure, and the oligonucleotide can be delivered into cells at even a relatively low-concentration dosage. Therefore, the oligonucleotide structure of the present invention can be useful as a novel type oligonucleotide delivery system as well as a tool for treating cancers, infectious diseases, and the like.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
14.
APPARATUS AND METHOD FOR AUTOMATICALLY ANALYZING BIOLOGICAL SAMPLES
The present invention relates to an apparatus and method for automatically analyzing biological samples, which: dissolve a biological sample in a hydrolase and cell lysate, and dissolve nucleic acid in a solvent, and then attach same to magnetic particles and wash same; and then ultimately wash same using an organic solvent and dry the magnetic particles using a vacuum pump; and then liquate a target nucleic acid attached to the magnetic particles in a solvent; and then apply same to a vessel including a nucleic acid-based amplification reagent and mix same; and then adjust the temperature for amplification and simultaneously irradiate excitation light at a reactor and detect amplification in real time by measuring fluorescent light, deactivate the amplified product by using an infrared lamp after the amplification, and then acquire an image through electrophoresis; and use one apparatus for the entire process of analyzing molecular mass. Thus, after mounting biological sample kits, an electronically automated process can be implemented in order to perform a qualitative and quantitative inspection having a high level of accuracy and reproducibility. In particular, an infrared lamp is provided having a movable function in order to concentrate radiation on an amplified product and to deactivate a genetically amplified product. Thus, false-positives can fundamentally be prevented.
The present invention relates to a double-helical oligo-RNA structure and a method for manufacturing same, and more specifically, to a double-helical oligo-RNA structure in which a polymeric compound is connected to the double-helical oligo-RNA by means of a covalent bond to improve the biosatbility of the double-helical oligo-RNA and enhance cell delivery efficency, and to a method for manufacturing the structure. In the double-helical oligo-RNA structure having the optimum structure, as described above, a function of the double-helical oligo-RNA is not compromised, and the double-helical oligo-RNA can be delivered to cells even with a small dose of relatively low concentration due to the stability of the double-helical oligo-RNA and efficient enhancement of a cell membrane penetration function, can be efficiently enhanced, and thus can be useful as a tool for treating double-helical oligo-RNA in cancer and infectious diseases and as a novel form of a double-helical oligo-RNA delivery system.
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
The present invention provides a double-stranded RNA structure, which comprises a polymer compound covalently bonded to a double-helix oligo RNA useful for the treatment of diseases, particularly cancer, in order to enhance the delivery of the double-helix oligo RNA, and further comprises a target-specific ligand bonded thereto, a preparation method thereof, and a technique of delivering the double-helix oligo RNA in a target-specific manner using the RNA structure. A nanoparticle composed of the ligand-bonded double-helix oligo RNA structures can efficiently deliver the double-helix oligo RNA to a target, and thus can exhibit the activity of the double-helix oligo RNA even when the double-helix oligo RNA is administered at a relatively low concentration. Also, it can prevent the non-specific delivery of the double-helix oligo RNA into other organs and cells. Accordingly, the ligand-bonded double-stranded RNA structure can be used for the treatment for various diseases, particularly cancer, and can also be effectively used as a new type of double-helix oligo RNA delivery system. Particularly, the ligand-bonded double-stranded RNA structure can be effectively used for the treatment of diseases, including cancer and infectious diseases. Moreover, the present invention relates to a hybrid conjugate, which comprises a hydrophilic material and hydrophobic material bonded to both ends of an antisense oligonucleotide (ASO) by a covalent bond in order to enhance the in vivo stability of the ASO, a method for preparing the hybrid conjugate, and a nanoparticle composed of the conjugates. The ASO-polymer conjugate according to the invention can increase the in vivo stability of the ASO, making it possible to efficiently deliver the therapeutic ASO into cells. Also, the ASO-polymer conjugate can exhibit the activity of the ASO even when it is administered at a relatively low concentration.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
17.
COMPOUND FOR INHIBITING ACTIVITY OF RIBONUCLEASE, AND CONTAINER FOR STORING NUCLEIC ACID CONTAINING THE SAME
Provided are an RNase activity inhibitory compound to effectively control the activity of the RNase promoting degradation of extracted RNAs and, in addition, a sample storage container including the same. The RNase activity inhibitory compound and the sample storage container according to the present invention may be effectively used to store RNAs during RNA extraction or the extracted RNAs.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C07D 231/46 - Oxygen atom in position 3 or 5 and nitrogen atom in position 4
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Provided are an siRNA-polymer conjugate, and a method for preparing the same, and more specifically, to a hybrid conjugate formed by covalently bonding siRNA and a polymeric compound for improving the in vivo stability of siRNA, and to a preparation method of the hybrid conjugate. The conjugate of the present invention can improve the in vivo stability of siRNA, thereby achieving an efficient delivery of therapeutic siRNA into cells and exhibiting the activity of siRNA even with a small dose of a relative low concentration. Therefore, the conjugate can advantageously be used as not only an siRNA treatment tool for cancers and other infectious disease, but also a novel type siRNA delivery system.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C08G 65/32 - Polymers modified by chemical after-treatment
C12N 15/11 - DNA or RNA fragments; Modified forms thereof
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
19.
METHOD OF INTEGRATED REAL-TIME NUCLEIC ACID ANALYSIS FOR SIMULTANEOUSLY DETECTING A PLURALITY OF TARGET NUCLEIC ACIDS
A method for simultaneously detecting a plurality of target nucleic acids, performed by an integrated real-time nucleic acid analysis system comprising a plurality of automated separation and purification instruments, a real-time nucleic acid amplifier and a controller. The method comprises separating and purifying nucleic acids from a plurality of biological samples and standard samples, simultaneously amplifying each target nucleic acid and performing at least one of qualitative analysis and quantitative analysis on the target nucleic acid, wherein a primer set and a probe is added to each reaction tube for amplifying and detecting each target nucleic acid, wherein each primer is different but has a similar melting point (Tm) and each probe is different but has a similar melting point (Tm) so that simultaneously amplifying and analyzing the nucleic acids can be performed under the same thermal condition.
Provided is a real-time monitoring apparatus, including a thermal cycling reaction block having heating block which is formed of a hollow part and divided by an insulating layer, and a capillary tube through which a sample is flowed in and/or out and which is wound on the heating block so that different temperatures are transferred and thus reaction cycle is repeatedly performed a light source; a band pass filter; a condensing lens; a beam splitter a reflecting mirror which is rotatably connected with a motor so as to transfer the excitation light reflected from the beam splitter to the capillary tube and reflect the fluorescence generated from the sample in the capillary tube; and a fluorescence detecting part.
KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (Republic of Korea)
BIONEER CORPORATION (Republic of Korea)
Inventor
Kim, Sun-Hwa
Jeong, Ji-Hoon
Park, Tae-Gwan
Abstract
Disclosed are hybrid conjugates formed by covalently bonding siRNA (small interfering RNA) molecules to hydrophilic polymers for improving stability of the siRNA molecules effective for gene therapy in vivo, and polyelectrolyte complex micelles formed by ionic interactions between the conjugates and multifunctional cationic compounds. The siRNA-hydrophilic polymer conjugates and polyelectrolyte complex micelles derived therefrom can be advantageously used for improving stability of the siRNA molecules in vivo. Consequently, the delivery of siRNA molecules for therapeutic applications into cells can be facilitated, and the siRNA is still active even though a small dose of the siRNA is used.